Literature DB >> 14720172

The neuropathology of frontotemporal lobar degeneration with respect to the cytological and biochemical characteristics of tau protein.

S Taniguchi1, A M McDonagh, S M Pickering-Brown, Y Umeda, T Iwatsubo, M Hasegawa, D M A Mann.   

Abstract

Pathological examinations, using a panel of tau and other antibodies, were performed on the brains from 55 consecutively acquired cases of frontotemporal lobar degeneration (FTLD). Clinically, these comprised 31 cases of frontotemporal dementia (FTD), 10 cases of motor neurone disease inclusion dementia (MNDID), seven cases of progressive aphasia (PA), four cases of semantic dementia (SD) and three cases of progressive apraxia (PAX). Tau pathology, in the form of neurofibrillary tangles (NFTs) and glial cell tangles, was present in six cases of FTD with parkinsonism linked to chromosome 17, five of these cases resulting from +16 splice-site mutation and one from +13 mutation in the tau gene. The insoluble tau proteins were comprised mostly of four-repeat (4-R) isoforms. Eight other cases of FTD, one of PA and all three cases of PAX showed tau-positive inclusions (Pick bodies) and swollen cells (Pick cells), characteristic of Pick's disease. In these cases, the insoluble tau proteins were present in most instances as three-repeat (3-R) tau isoforms, although two cases with a mixture of 3-R and 4-R isoforms were seen. One other case of FTD showed an unusual pathology characterized by massive extracellular deposition of tau protein, composed of 4-R tau isoforms, within white matter without neuronal or glial cell inclusions. However, 33 (60%) of 55 FTLD cases showed no tau pathology in the brain, except for the rare NFTs, composed of a mix of 3-R and 4-R isoforms, in some of the more elderly cases. Of these 33 cases, 13 had FTD, 10 had MNDID, six had PA and four had SD. The pathological changes present were those of a superficial cortical laminar microvacuolation with mild subpial and subcortical gliosis; the 10 MNDID cases had ubiquitin-positive inclusions in the cerebral cortex and hippocampus. These 33 nontau FTLD cases, along with five Alzheimer's disease (AD) and six Huntington's disease (HD) cases with severe pathology, showed a variable loss of soluble tau proteins, broadly comparable with the extent of neuronal loss from the cortex and loss of the intracortical perikaryal marker, NeuN, but unrelated to proteins within afferent projection fibres such as neurofilament and alpha-synuclein. Levels of tau mRNA were decreased in parallel in the tau-negative FTLD cases and in the severe AD and HD cases. Hence, the loss of tau from these 33 nontau FTLD cases is just one aspect of a neurodegenerative process that destroys many components of the nerve cell machinery and does not represent a specific disordering of the cell's ability to form tau proteins or incorporate these into microtubules.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14720172     DOI: 10.1046/j.0305-1846.2003.00481.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  18 in total

1.  A Novel Tau Mutation in Exon 12, p.Q336H, Causes Hereditary Pick Disease.

Authors:  Pawel Tacik; Michael DeTure; Kelly M Hinkle; Wen-Lang Lin; Monica Sanchez-Contreras; Yari Carlomagno; Otto Pedraza; Rosa Rademakers; Owen A Ross; Zbigniew K Wszolek; Dennis W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2015-11       Impact factor: 3.685

Review 2.  Frontotemporal dementia.

Authors:  Erik D Roberson
Journal:  Curr Neurol Neurosci Rep       Date:  2006-11       Impact factor: 5.081

Review 3.  Neuropsychological differences between frontotemporal dementia and Alzheimer's disease: a review.

Authors:  Michal Harciarek; Krzysztof Jodzio
Journal:  Neuropsychol Rev       Date:  2005-09       Impact factor: 7.444

4.  Novel progranulin mutation detected in 2 patients with FTLD.

Authors:  Lena Skoglund; Toshifumi Matsui; Stefanie H Freeman; Anders Wallin; Elin S Blom; Matthew P Frosch; John H Growdon; Bradley T Hyman; Lars Lannfelt; Martin Ingelsson; Anna Glaser
Journal:  Alzheimer Dis Assoc Disord       Date:  2011 Apr-Jun       Impact factor: 2.703

5.  Voxel-based morphometry patterns of atrophy in FTLD with mutations in MAPT or PGRN.

Authors:  J L Whitwell; C R Jack; B F Boeve; M L Senjem; M Baker; R Rademakers; R J Ivnik; D S Knopman; Z K Wszolek; R C Petersen; K A Josephs
Journal:  Neurology       Date:  2009-03-03       Impact factor: 9.910

Review 6.  Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions.

Authors:  Victor L Villemagne; Vincent Doré; Samantha C Burnham; Colin L Masters; Christopher C Rowe
Journal:  Nat Rev Neurol       Date:  2018-02-16       Impact factor: 42.937

Review 7.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

8.  Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration.

Authors:  Nigel J Cairns; Eileen H Bigio; Ian R A Mackenzie; Manuela Neumann; Virginia M-Y Lee; Kimmo J Hatanpaa; Charles L White; Julie A Schneider; Lea Tenenholz Grinberg; Glenda Halliday; Charles Duyckaerts; James S Lowe; Ida E Holm; Markus Tolnay; Koichi Okamoto; Hideaki Yokoo; Shigeo Murayama; John Woulfe; David G Munoz; Dennis W Dickson; Paul G Ince; John Q Trojanowski; David M A Mann
Journal:  Acta Neuropathol       Date:  2007-06-20       Impact factor: 17.088

9.  Efficacy of memantine on neuropsychiatric symptoms associated with the severity of behavioral variant frontotemporal dementia: A six-month, open-label, self-controlled clinical trial.

Authors:  Pan Li; Wei Quan; Yu-Ying Zhou; Yan Wang; Hui-Hong Zhang; Shuai Liu
Journal:  Exp Ther Med       Date:  2016-04-20       Impact factor: 2.447

10.  Plasma phosphorylated-TDP-43 protein levels correlate with brain pathology in frontotemporal lobar degeneration.

Authors:  Penelope G Foulds; Yvonne Davidson; Manjari Mishra; David J Hobson; Kirsty M Humphreys; Mark Taylor; Nancy Johnson; Sandra Weintraub; Haruhiko Akiyama; Tetsuaki Arai; Masato Hasegawa; Eileen H Bigio; Fiona E Benson; David Allsop; David M A Mann
Journal:  Acta Neuropathol       Date:  2009-10-13       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.